How This New Biotech Billionaire Outmaneuvered Merck In China:
Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech ...
forbes.com/sites/kerryadolan/2025/07/16/how-this-new-biotech-billionaire-outmaneuvered-merck-in-china/
Story Details
| Last Updated | |
| Total Articles | 5 |
Main Topics
agency of the US Department of Health and Human Services
More articles on this subject
Previous
How This New Biotech Billionaire Outmaneuvered Merck In China: Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech ...
forbes.com/sites/kerryadolan/2025/07/16/how-this-new-biotech-billionaire-outmaneuvered-merck-in-china/
Next
Similar to This
Previous
STAT Jul 15
Celcuity’s breast cancer drug approved, its first: FDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The ...
statnews.com/2026/07/15/biotech-news-celcuity-breast-cancer-drug-approved-in-a-first/
Paid articlePaywall
Personalizing Antithrombotic Care: A Case-Based Look at Factor XIa Inhibition After Stroke
medscape.org/viewarticle/personalizing-antithrombotic-care-case-based-look-factor-xia-2026a1000j4a
Wrestling Inc. Jul 10
Xia Brookside Retains Knockouts Title After No DQ Match On TNA Impact: Xia Brookside retains the TNA Knockouts World Championship in her first title defense in ...
wrestlinginc.com/2212078/tna-impact-xia-brookside-lei-ying-lee-retains-knockouts-title-no-dq/
Pill offers hope in treating deadly pancreatic cancer: Pill users lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy
theweek.com/health/pill-offers-hope-pancreatic-cancer
STAT May 31
A standing ovation for RevMed, and caution for Akeso: A standing ovation for a pancreatic cancer treatment, a new approach for immunotherapy ...
statnews.com/2026/05/31/asco-news-day-3-revmed-akeso-summit-lilly-kelonia/
Paid articlePaywall
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
cnbc.com/2026/05/31/asco-summit-akeso-ivonescimab-improves-survival-in-harmoni-6-trial.html
Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial
reuters.com/business/healthcare-pharmaceuticals/akeso-lung-cancer-drug-helps-patients-live-15-longer-than-immunotherapy-china-2026-05-31/
STAT May 31
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer: Ivonescimab, also being developed by Summit, exceeds expectations at ASCO ...
statnews.com/2026/05/31/squamous-cell-lung-cancer-akeso-summit-harmoni-asco-2026/
Paid articlePaywall
Lung Cancer Patients on Drug From China’s Akeso Lived Longer: A lung cancer drug developed by Akeso Inc. extended patients’ lives by about four months in a ...
bloomberg.com/news/articles/2026-05-31/lung-cancer-patients-on-drug-from-china-s-akeso-lived-longer
Paid articlePaywall STAT Apr 30
What does Akeso’s primo plenary spot say about its survival data?: In the runup to the American Society of Clinical Oncology, good bit of the Wall Street chatter ...
statnews.com/2026/04/30/akeso-summit-therapeutics-drug-ivonescimab-results-announced-asco/
Paid articlePaywall
How Michelle Xia outmaneuvered Merck in China: Akeso CEO Xia gained experience in the US before launching her own biotech company back home in China ...
forbesindia.com/article/global-game/cross-border/biotech-billionaire/2988107/1
Next